Status and phase
Conditions
Treatments
About
The purpose of this study is to investigate the effect of combined topotecan and veliparib (ABT888) treatment in relapsed ovarian cancer with tumor progression and negative or unknown BRCA mutation status.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer.
Verified progression by either RECIST criteria and/or GCIG CA125 criteria after previous first line chemotherapy or progression after later lines of cytotoxic treatment.
Platinum resistance or partially platinum sensitive disease
Age ≥ 18 years.
Performance status 0-2.
Measurable disease by RECIST 1.1 or CA125 GCIG criteria
Adequate bone marrow function, liver function, renal function and coagulation parameters (within 7 days prior to enrollment):
Written informed consent.
Tissue available for BRCAness analysis/BRCA mutation analysis.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
22 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal